www.QualityStocks.Net would like to highlight Adolor Corp. (NASDAQ: ADLR). The company is a development-stage biopharmaceutical company. The Company has specialized in the discovery and development of prescription pain management products. It has a number of product candidates in various stages of development, ranging from preclinical studies to pivotal clinical trials.
In the company’s news yesterday,
Adolor Corporation appointed John M. Limongelli, Esq., as general counsel, managing all legal affairs for the company. Mr. Limongelli will also be a senior vice president, reporting directly to Adolor president and CEO Michael Dougherty.
Mr. Limongelli comes from a much larger corporate environment, Cephalon, Inc., a global pharmaceutical company with annual sales approaching $2 billion, where he was associate general counsel and vice president. Prior to that he was with one of the world’s largest law firms, Morgan, Lewis & Bockius out of Philadelphia, and is a graduate of Temple University.
“As Adolor continues its transition to a commercial stage pharmaceutical company, John’s industry and private practice experience will prove to be an invaluable asset to the company” said Dougherty.
Adolor (www.Adalor.com) was founded in 1993. Located just outside of Philadelphia, it has approximately 115 employees engaged in pharmaceutical research and production. Research efforts have targeted the development of products to maintain or enhance the effectiveness of pain relief pharmaceuticals, while reducing or eliminating negative side effects.
Adolor’s primary product is Entereg®, used for gastrointestinal surgery patients, where it is designed to block the negative effects of opioids, such as morphine, without reducing pain relief. Entereg® is also in late-stage development for the management of OBD (opioid-induced bowel dysfunction). Adolor has a collaboration agreement with GlaxoSmithKline (GSK) for the exclusive worldwide development and commercialization of Entereg®, and also collaborates with Pfizer (PFE).
In spite of ongoing challenges in the area of sales and FDA approvals, Adolor continues to feed its pipeline for future products and applications. Rolling earnings-per-share, though still in negative territory, has increased dramatically over the past year, and has now surpassed what it was in early 2006 when Adolor’s share price was in the $20s.
About QualityStocks
QualityStocks, based in Scottsdale, Arizona is a free service that collects data from hundreds Small-Cap and Micro-Cap online Investment Newsletters into one Free Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their advertising efforts and now has over 500,000+ subscribers that receive The Daily Stock Newsletters.
To sign up for “The QualityStocks Daily Newsletter” please visit http://www.qualitystocks.net/
Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
